These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16877042)

  • 1. Registry data evaluating the effectiveness of drug-eluting stents for the treatment of symptomatic in-stent restenosis.
    Worthley MI; Anderson TJ; Traboulsi M; Charbonneau F; Curtis MJ; Hansen JL; Knudtson ML; Spence FP; Goodhart DM
    Heart Lung Circ; 2006 Oct; 15(5):300-5. PubMed ID: 16877042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-eluting stents for the treatment of in-stent restenosis--'real world' double centre experience in consecutive patients.
    Anderson RA; Fath-Ordoubadi F; Younas S; Bainbridge A; Swallow RA; Dawkins KD; Curzen NP
    Int J Cardiovasc Intervent; 2005; 7(4):188-92. PubMed ID: 16373265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late restenosis following placement of a sirolimus eluting stent for in-stent restenosis.
    Ali OA; Lowe H; Kritharides L; Brieger D
    Heart Lung Circ; 2007 Feb; 16(1):50-1. PubMed ID: 17196881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immediate and long-term outcomes of drug-eluting stent implantation for unprotected left main coronary artery disease: comparison with bare-metal stent implantation.
    Gao RL; Xu B; Chen JL; Yang YJ; Qiao SB; Li JJ; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J
    Am Heart J; 2008 Mar; 155(3):553-61. PubMed ID: 18294496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of drug-eluting stents in-stent restenosis with paclitaxel-coated balloon angioplasty: Insights from the French "real-world" prospective GARO Registry.
    Auffret V; Berland J; Barragan P; Waliszewski M; Bonello L; Delarche N; Furber A; Albert F; Carrié D; Eltchaninoff H; Pansieri M; Schneeberger M; Piot C; Marcollet P; Bedossa M
    Int J Cardiol; 2016 Jan; 203():690-6. PubMed ID: 26583844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.
    Mehilli J; Byrne RA; Tiroch K; Pinieck S; Schulz S; Kufner S; Massberg S; Laugwitz KL; Schömig A; Kastrati A;
    J Am Coll Cardiol; 2010 Jun; 55(24):2710-6. PubMed ID: 20226618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of drug-eluting balloon in patients with bare-metal or drug-eluting stent restenosis.
    Berta B; Jambrik Z; Kohar K; Szabo G; Ruzsa Z; Molnar L; Barczi G; Geller L; Becker D; Merkely B
    Hellenic J Cardiol; 2014; 55(5):369-77. PubMed ID: 25243435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus-eluting stent implantation for bare-metal in-stent restenosis: is there any evidence for a late catch-up phenomenon?
    Sheiban I; Chiribiri A; Galli S; Biondi-Zoccai G; Montorsi P; Beninati S; Fabbiocchi F; Moretti C; Omedè P; Trabattoni D; Lotrionte M; Trevi GP; Bartorelli AL
    J Cardiovasc Med (Hagerstown); 2008 Aug; 9(8):783-8. PubMed ID: 18607241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of angiographic and clinical outcomes after sirolimus-eluting versus paclitaxel-eluting stents for the treatment of in-stent restenosis.
    Li JJ; Xu B; Yang YJ; Ma WH; Chen JL; Qiao SB; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
    Chin Med J (Engl); 2006 Jul; 119(13):1059-64. PubMed ID: 16834923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Taxus polymer-coated paclitaxel-eluting stents for treatment of in-stent restenosis in real world patients: results of clinical and angiographic follow-up at six months in a single-center registry.
    Lim VY; Buellesfeld L; Gerckens U; Mueller R; Schmidt T; Grube E
    Catheter Cardiovasc Interv; 2006 Sep; 68(3):343-8. PubMed ID: 16897778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses.
    Markovic S; Paliskyte R; Rottbauer W; Wöhrle J
    Cardiovasc Revasc Med; 2012; 13(6):307-10. PubMed ID: 23164475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between sirolimus-eluting stents and intracoronary catheter-based beta radiation for the treatment of in-stent restenosis.
    Feres F; Muñoz JS; Abizaid A; Albertal M; Mintz GS; Staico R; Centemero M; Mattos LA; Maldonado G; Tanajura LF; Chaves A; Pinto I; Abizaid AS; Seixas AC; Vaz VD; Sousa A; Sousa JE
    Am J Cardiol; 2005 Dec; 96(12):1656-62. PubMed ID: 16360353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restenosis treatment in the drug-eluting stent era.
    Presbitero P; Boccuzzi G
    Ital Heart J; 2005 Jun; 6(6):514-21. PubMed ID: 16008157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
    Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
    Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
    Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K
    J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation.
    Song HG; Park DW; Kim YH; Ahn JM; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Han S; Seong IW; Lee NH; Lee BK; Lee K; Lee SW; Nah DY; Park SJ
    J Am Coll Cardiol; 2012 Mar; 59(12):1093-100. PubMed ID: 22421303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of coronary artery bypass grafting following implantation of a paclitaxel-eluting or a bare-metal stent into a single coronary artery.
    Martin JL; Ellis SG; Colombo A; Grube E; Maloney T; Friedman MI; Baim DS; Dawkins K; Caputo R; Stone GW
    Am J Cardiol; 2009 Jan; 103(1):11-6. PubMed ID: 19101222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of overlapping heterogenous drug-eluting stents and of overlapping drug-eluting and bare metal stents.
    Burzotta F; Siviglia M; Altamura L; Trani C; Leone AM; Romagnoli E; Mazzari MA; Mongiardo R; Niccoli G; Brancati M; Biondi-Zoccai G; Rebuzzi AG; Schiavoni G; Crea F
    Am J Cardiol; 2007 Feb; 99(3):364-8. PubMed ID: 17261399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of angiographic patterns of in-stent restenosis between sirolimus- and paclitaxel-eluting stent.
    Park CB; Hong MK; Kim YH; Park DW; Han KH; Lee CW; Kang DH; Song JK; Kim JJ; Park SW; Park SJ
    Int J Cardiol; 2007 Sep; 120(3):387-90. PubMed ID: 17291608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of sirolimus-eluting and Paclitaxel-eluting stents on outcome in patients with diabetes mellitus and stenting in more than one coronary artery.
    Stankovic G; Cosgrave J; Chieffo A; Iakovou I; Sangiorgi G; Montorfano M; Airoldi F; Carlino M; Michev I; Finci L; Colombo A
    Am J Cardiol; 2006 Aug; 98(3):362-6. PubMed ID: 16860024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.